Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-12
2006-09-12
Priebe, Scott D. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C424S093200, C424S093210
Reexamination Certificate
active
07105494
ABSTRACT:
The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.
REFERENCES:
patent: 5032407 (1991-07-01), Wagner et al.
patent: 5460959 (1995-10-01), Mulligan et al.
patent: 5650096 (1997-07-01), Harris et al.
patent: 5665350 (1997-09-01), Quesenberry
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5674844 (1997-10-01), Kuberasampath et al.
patent: 5719131 (1998-02-01), Harris et al.
patent: 5750103 (1998-05-01), Cherskey
patent: 5763416 (1998-06-01), Bonadio et al.
patent: 5767099 (1998-06-01), Harris et al.
patent: 5824655 (1998-10-01), Border
patent: 5844079 (1998-12-01), Ingham et al.
patent: 5858355 (1999-01-01), Glorioso et al.
patent: 5910487 (1999-06-01), Yew et al.
patent: 5912239 (1999-06-01), Siegel et al.
patent: 5942496 (1999-08-01), Bonadio et al.
patent: 5948767 (1999-09-01), Scheule et al.
patent: 5948925 (1999-09-01), Keynes et al.
patent: 5952516 (1999-09-01), Siegel et al.
patent: 5981275 (1999-11-01), Armentano et al.
patent: 6090790 (2000-07-01), Eriksson
patent: 6737413 (2004-05-01), Koopman et al.
patent: 890639 (1999-01-01), None
patent: 9118047 (1991-11-01), None
patent: 9207943 (1992-05-01), None
patent: 9514232 (1995-05-01), None
patent: 9527518 (1995-10-01), None
patent: WO 9617057 (1996-06-01), None
patent: 9623001 (1996-08-01), None
patent: 9722623 (1997-06-01), None
patent: 9806849 (1998-02-01), None
patent: 9813383 (1998-04-01), None
patent: 9921589 (1999-05-01), None
Alden et al., “The use of bone morphogenetic protein gene therapy in craniofacial bone repair,” J. Craniofacial Surg. 11(3): 167-175, Jan. 2000.
Graham et al, “Characteristics of a human cell line transformed by DNA from Human Adenovirus”,J. Gene Virol.,vol. 36, 1977, pp. 59-72.
Srivastava et al., “Nucleotide sequence organization of the adeno-associated virus 2 genome”,J. Virol.,vol. 45, 1983, pp. 555-564.
Sampath et al., “Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein by heparin affinity chromatography”,Proc. Natl. Acad. Sci. USA, vol. 84, 1987, pp. 7109-7113.
Zaslav et al., “Management of resistant pseudoarthrosis of long bones”,Clin. Orthop. Rel. Res., vol. 233, 1988, pp. 234-242.
Yamaguchi et al., “Recombinant human BMP-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro”,J. Cell. Biol.,vol. 113, 1991, pp. 681-687.
Hammonds et al., “Bone inducing activity of mature BMP-2b produced from a hybrid BMP-2 a/b precursor”,Mol. Endocrinol.,vol. 5, 1991, pp. 149-155.
Gao et al., “A novel cationic lipsome reagent for efficient transfetion of mammalian cells”,Biochem. Biophys. Res. Commun.,vol. 179, 1991, pp. 280-285.
Albertson et al., “The use of periosteally vascularized autografts to augment the fixation of large segmental allografts”,Clin. Orthop.,vol. 269, 1991, pp. 113-119.
Yasko et al., “The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP)”,J. Bone Joint Surg.,vol. 74-A, 1992, pp. 659-670.
Minami et al., “Treatment of infected segmental defect of long bone with vascularized bone transfer”,J. Reconstr. Microsurg.,vol. 8, 1992, pp. 75-82.
Aspenberg et al., “Bone morphogenetic protein induces bone in the squirrel monkey, but bone matrix does not”,Acta Orthop. Scand.,vol. 63, 1992, pp. 619-622.
Wang et al., “Bone morphogenetic proteins (BMPs): therapeutic potential in healing bony defects”,Trends Biotechnol.,vol. 11, 1993, pp. 379-383.
Südkamp et al., “Incidence of non-unions in open fractures: analysis of 948 open fractures”,Akt Traumatol, vol. 23, 1993, pp. 59-67.
Sampath et al., “Drosophila TGF-β superfamily proteins induce endochrondral bone formation in mammals”,Proc. Natl. Acad. Sci. USA, vol. 90, 1993, pp. 6004-6008.
Gerhart et al., “Healing segmental femoral defects in sheep using recombinant human one morphogenetic protein”,Clin. Ortop. Rel. Res.,vol. 293, 1993, pp. 317-326.
Bandara et al., “Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer”,Proc. Natl. Acad. Sci. USA, vol. 90, 1993, pp. 10764-10768.
Schwartz et al., “IL-1 receptor antagonist (IRAP) inhibits IL-8 production in A549 cells infected with a replication deficient recombinant adenovirus”,FASEB J.,1994, vol. 8, pp. 4-5.
Kimble et al., “Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats,”J. Clin. Invest.,vol. 93, 1994, pp. 1959-1967.
Katagiri et al., “BMP-2 converts the differentiation pathway of C2C12 myoblasts into the osteblast lineage”,J. Cell Biol.,vol. 6, 1994, pp. 1755-1766.
Wells et al., “The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long term initiatine cells (LTCICs) from the bone marrow of a patient with Gaucher disease”,Gene Therapy, vol. 2, 1995, pp. 512-520.
Evans et al., “Possible orthopedic applications of gene therapy”,J. Bone Joint Surg.,vol. 77-A, 1995, pp. 1103-1114.
Einhorn et al., “Enhancement of fracture healing”,J. Bone Joint Surg.,vol. 77-A, 1995, p. 940-955.
Baragi et al., “Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation”,J. Clin. Invest.,vol. 96, 1995, pp. 2454-2460.
Wehling et al., “Neurophysiologic changes in lumbar nerve root inflammation in the rate after treatment with cytokine inhibitors”,Spine, vol. 21, 1996, pp. 931-935.
Smith et al., “Gene delivery systems for use in gene therapy an overview of quality assurance and safety issues”,Gene Therapy, vol. 3, 1996, pp. 190-200.
Riley et al., “Bone morphogenetic protein-1: biology and applications,”Clin. Orthop.,vol. 324, 1996, pp. 39-46.
Mittereder et al., “Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy”,J. Virol.,vol. 70, 1996, pp. 7498-7509.
Lind et al., “Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and US-OS cells”,Bone, vol. 18, 1996, pp. 53-57.
Fang et al., “Stimulation of new bone formation by direct transfer of osteogenic plasmid genes”,Proc. Natl. Acad. Sci. USA, vol. 93, 1996, pp. 5753-5758.
Bostrom et al., “Use of BMP-2 in the rabbit ulnar nonunion model”,Clin. Orthop. Rel. Res.,vol. 327, 1996, pp. 272-282.
Ripamonti et al., “Recombinant transforming growth factor-β1 induces endochondral bone in the baboon and synergizes with recombinant osteogenic protein-1 (bone morphogenetic protein-7) to initiate rapid bone formation”,J. Bone Min. Res.,vol. 12, 1997, pp. 1584-1595.
Reinecke et al., “In vitro transfer of genes in spinal tissue,”Z. Orthop. Ihre. Grenzgeb.,vol. 135, 1997, pp. 412-416.
Pelletier et al., “In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy”,Arthritis and Rheumatism, vol. 40, 1997,
Baltzer Axel W.
Evans Christopher H.
Robbins Paul D.
JHK Law
Kim Joseph Hyosuk
Priebe Scott D.
University of Pittsburgh of the Commonwealth System of Higher Ed
LandOfFree
Viral and non-viral vectors as vehicles for delivering... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral and non-viral vectors as vehicles for delivering..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral and non-viral vectors as vehicles for delivering... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3570914